Monday, Dec 10, 2018
engineered enzymes for better healthcare

半乳糖血症 (GAL) 是由于缺乏半乳糖(乳糖的一种成份)代谢所需的酶所导致的,新生儿的发病率大约为 1/40,000。爱尔兰流动社区的发病率为 1/450。患有 GAL 的新生儿通常看起来并无异常。但开始喂乳后几天内,就会出现呕吐、嗜睡、腹泻、黄疸病和肝脏损伤等症状。该疾病可能导致发育迟缓、生长障碍、白内障等,严重时还会导致死亡。通过早期发现和严格的无半乳糖饮食,患有 GAL 的新生儿可以恢复到令人满意的正常身体状况。

产品信息

amino-acid-disorders-product酶缺乏症紊乱

GAL           半乳糖血症

G6PD         葡萄糖-6-磷酸脱氢酶缺乏症

BIO           生物素酰胺酶缺乏症

Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...